Lykos Therapeutics
A public benefit corporation (PBC) developing investigational psychedelics to catalyze therapeutic approaches for mental health conditions.
As of Q2 2024, Lykos has completed two Phase III trials for post-traumatic stress disorder (PTSD) and submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for midomafetamine (MDMA) capsules used in combination with psychological intervention. If approved, it would be the first psychedelic-assisted therapy approved for PTSD.
Latest Lykos Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze